Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04076059 is registered in ClinicalTrials.gov with Astellas (Beijing) Pharmaceutical R&D Co., Ltd. as lead sponsor.

NCT NCT04076059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04076059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Lead sponsor
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 11, 2019
Completion date
December 31, 2028
Enrollment
180 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone sensitive prostate cancer